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ABSTRACT  
Objective The aim of this economic evaluation was to assess whether home 
management could represent a cost-effective strategy in the patient pathway of Type 
1 diabetes (T1D).  This is based on the DECIDE trial (ISRCTN78114042), which 
compared home versus hospital management from diagnosis in childhood diabetes 
and found no statistically significant difference in glycaemic control at 24 months. 
Design Cost-effectiveness analysis alongside a randomised controlled trial.  
Setting Eight paediatric diabetes centres in England, Wales and Northern Ireland. 
Participants 203 clinically well children aged under 17 years, with newly diagnosed 
type 1 diabetes and their carers. 
Outcome measures The base case analysis adopted an NHS perspective. A 
scenario analysis assessed costs from a broader societal perspective. The 
incremental cost-effectiveness ratio (ICER) expressed as cost per mmol/mol 
reduction in HbA1c, was based on the mean difference in costs between the home 
and hospital groups, divided by mean differences in effectiveness (HbA1c). 
Uncertainty was considered in terms of the probability of cost-effectiveness.  
Results At 24 months post-intervention, the base case analysis showed a difference 
in costs between home and hospital, in favour of home management (mean 
difference -£2,217; 95% CI -£2,825 to -£1,609; p<0.001). Home care dominated, with 
an ICER of £7,434 (saved) per mmol/mol reduction of HbA1c. The results of the 
scenario analysis also favoured home management. The greatest driver of cost 
differences was hospitalisation during the initiation period. 
Conclusions Home management from diagnosis of children with T1D who are 
medically stable represents a less costly approach for the NHS in the UK, without 
impacting clinical effectiveness. 
 
Strengths and limitations of this study  
• Cost-effectiveness analysis based on a randomised controlled trial, using 
patient-level data on resource use, collected prospectively. 
• Methods were consistent with the NICE reference case, as recommended for 
the NHS in the UK. 
• Quality-adjusted life years were not used as the health outcome and therefore 
interpretation of cost-effectiveness is more challenging. 
• Cost-effectiveness was assessed over the trial period only; lifetime 
extrapolation was not performed to identify long-term costs and benefits. 
• Clinical practice has evolved since the trial commenced and consequently 
resource use and costs will have changed. 
Trial registration number ISRCTN78114042  
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INTRODUCTION  
A diagnosis of Type 1 diabetes (T1D) poses a significant economic burden on 
healthcare systems, due to the resources required for effective management, the 
associated complications, and its life-long course. As a result, it is estimated that the 
National Health Service (NHS) spends £1billion a year on T1D; 11% of this 
expenditure is on inpatient care.[1]The cost of keeping someone in hospital is high 
and, as a result, there has been a growing emphasis on delivery of care within 
primary care and community settings.[2] Patients’ attitudes are also shifting towards 
wanting to be more involved in their own care and wishing to be treated closer to 
home, as highlighted in the NHS England Five Year Forward Plan.[3]  Evidence 
suggests that initial management of T1D can be successfully delivered at home 
rather than in hospital[4–6] although the cost-effectiveness of this approach is 
unknown in the UK. 
T1D affects 25.1 per 100,000 children and young people in the United Kingdom (UK) 
and the incidence is rising.[7] It is a life-long condition which can lead to serious 
short (e.g. diabetic ketoacidosis (DKA)) and long-term (e.g. renal, vascular and 
retinal damage) complications.[8] The risk of complications is reduced if blood 
glucose is kept within healthy targets.[9]To achieve this, the National Institute for 
Health and Care Excellence (NICE) recommends offering children and their families 
intensive education on insulin management from diagnosis and a long-term package 
of care, delivered through a multidisciplinary team. The NICE guidelines state that 
the choice of where this initial care is delivered should be made based on clinical 
need, family circumstances and wishes.[10] Hospitalisation has been shown to be a 
substantially stressful event for both the child and their parents[11] and so should be 
avoided unless clinically necessary. Most children with T1D are not acutely unwell at 
diagnosis and therefore could be managed at home.[6,12] 
However, there have been few, well-designed studies evaluating home versus 
hospital management. A Cochrane review in 2007 concluded that the results of prior 
studies were inconclusive but suggested that home management at diagnosis does 
not lead to any clinical, psychological or cost disadvantages.[5] Since this review, 
further randomised controlled trials (RCTs) have been conducted. One was carried 
out in Sweden, where home management was described as ‘hospital-based-home-
care’ as it involved staying in a facility which was designed to replicate a home 
environment but was located in the hospital grounds.[13] There was no difference 
between ‘hospital-based-home-care’ and ‘hospital care’, in terms of glycated 
haemoglobin (HbA1c) (mean difference between groups 0.6mmol/mol; p=0.777) but 
a cost-effectiveness analysis reported significantly lower healthcare (direct) costs in 
the home managed group (- SEK 16,212 (-£1,318); p<0.05).[13] 
More recently, the Delivering Early Care In Diabetes Evaluation (DECIDE) RCT 
evaluated home versus hospital management at diagnosis in childhood diabetes.[14] 
It was conducted between 2008-2013 in eight paediatric diabetes centres in 
England, Wales and Northern Ireland. . The primary outcome was HbA1c at 24 
months post-diagnosis and secondary outcomes included coping, anxiety, quality of 
life (QoL) and use of NHS resources. The trial found no statistically significant 
difference in HbA1c between home and hospital management (1.01mmol/mol, 95% 
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CI 0.93 to 1.09) and there were no differences in secondary outcomes at 24 months, 
other than a higher self-esteem in children who were managed at home. 
The aim of the present analysis was to estimate the cost effectiveness of home 
versus hospital management of children diagnosed with T1D from the perspective of 
the NHS in the UK.  
METHODS  
The DECIDE trial protocol and results are described in detail elsewhere.[14,15] 
Briefly, DECIDE was a superiority RCT, designed to compare the clinical 
effectiveness of home care from diagnosis with hospital-based care in the 
management of T1D. The sample size needed to detect a difference in mean HbA1c 
of 5 mmol/mol (with an SD of 14 mmol/mol; equivalent to an effect size of 0.4) was 
200 participants (100 per group) at a 5% significance level and 80% power.  
Following informed consent, 203 clinically well children aged less than 17 years old 
with newly diagnosed diabetes, from eight paediatric diabetes centres across the 
UK, were randomised to home or hospital management. Participants were eligible to 
take part if they or their carers were deemed able to complete the study 
requirements and gave informed assent or consent. Participants were excluded if 
they were not medically stable at diagnosis or required hospitalisation for other 
reasons. Full inclusion and exclusion criteria are described in the trial protocol.[15] 
The economic evaluation considered the intention to treat population. 
Trial governance 
Multicentre approval was granted by Research Ethics Committee for Wales 
(07/MRE09/59). Site-specific approval was granted by participating Acute Trust 
Research and Development Departments. The trial sponsor was Cardiff University.  
Study perspective 
The base case analysis of this economic evaluation follows the cost perspective of 
the NHS[16]. Indirect costs (impact on productivity) and direct non-medical costs 
(incurred by the patient and his/her carer) were also evaluated through separate 
scenario analyses as T1D has been shown to have wider economic impacts.[17]  
Intervention and comparator   
The intervention involved management of the initiation period from diagnosis in the 
family’s own home, for a minimum of 3 days, to include at least six supervised 
injections and delivery of pragmatic educational care. This meant that children were 
discharged on the day of diagnosis, with no overnight stays in hospital. All 
subsequent management, education (diabetes and dietetic) was provided by nursing 
staff and dietitians either in the child’s home or as an outpatient. In comparison, 
participants in the hospital group were admitted to hospital on the day of diagnosis, 
for a minimum of three days and received education and support in line with local 
practice.  
Discount rate  
A discount rate of 3.5% per annum was applied to costs and consequences after 12 
months, as recommended by NICE.[16] We used this rate because all economic 
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evaluations require that future costs and effects are discounted to present value to 
account for time preference. In the UK, the discount rate is set at 3.5% per annum. 
Estimating resources and costs  
Data on resource use were collected using case report forms (CRFs) at baseline, 
then at 3, 12 and 24 months which were summed to calculate total resource use 
over 24 months (Supplementary Materials Table 1). Baseline data comprised of data 
collected from the day of diagnosis until day 3 of either home or hospital 
management. Resource use prior to diagnosis was not included.  
The base case analysis considered direct NHS resource use. This encompassed 
hospital stay, tests and investigations, insulin usage, nurse and dietician travel, and 
contacts with healthcare professionals. 
Contacts with healthcare professionals, along with distance travelled, was collected 
with each CRF. These were costed using the PSSRU 2019 compendium of NHS unit 
costs.[18] 
The unit costs of a paediatric overnight hospital stay were sourced from the NHS 
Reference Costs database 2019/20.[19] 
Tests and investigations were costed through contacting the Biochemistry and 
Immunology Department within the University Hospital of Wales, the main centre for 
the trial. Unit costs not provided were inflated from previously supplied figures from 
Cwm Taf Health Board to 2019/20 figures, using the CCEMG-EPPI-Centre Cost 
Converter.[20]  
Insulin regimen data were collected at all time points. This included type of insulin, 
number of units prescribed throughout the day and related equipment usage (at 
follow-up only). Medical equipment included items such as testing strips, needles, 
and lancets.The British National Formulary for Children (BNFc) and the NHS 
Electronic Drug Tariff were used to reference insulin costs and equipment.[21,22] 
Broader perspectives, considering non-healthcare resource use, were adopted in 
scenario analyses. These covered productivity losses incurred by the patient and 
their family (indirect costs), including days off school and work, as well as travel and 
out of pocket expenses (direct costs) related to managing T1D. Days taken off work 
were costed based on average salary earnings in the UK.[23] Time taken off school 
was costed based on calculating an average cost spent per pupil per day, based on 
the Annual Report on Education Spending in England.[24] Reported out of pocket 
expenses incurred by patients and their carers were inflated to 2019/20 costs using 
the UK Consumer Price Index.[25] 
Currency and cost year  
Costs were reported in British pounds sterling for 2019/20. 
Choice of model  
The results of the main DECIDE trial demonstrated no statistically significant clinical 
difference between home and hospital groups and therefore it was deemed that an 
evaluation of lifetime costs using an economic model was neither necessary nor 
informative.  
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Assumptions  
The CRFs did not collect data on length of consultations with healthcare 
professionals and so assumptions were made based on PSSRU data and through 
communication with healthcare professionals. Further assumptions relating to the 
calculation and estimation of costs are reported in Supplementary Materials Tables 
2-7. 
Outcome measures and economic analysis  
The primary measure of clinical effectiveness was HbA1c at 24 months. As 
alternative measures to enable the calculation of quality-adjusted life years (QALYs) 
were not used in DECIDE, HbA1c was used as the measure of effect for the cost-
effectiveness analysis.  
The mean total costs of each scenario were calculated for both the intervention and 
control groups over 24 months. This follow-up period was chosen as it was expected 
that most participants would have no significant endogenous insulin secretion by this 
time point. Costs are also reported for the initiation period (0-3 days). 
Cost-effectiveness was assessed through estimation of the incremental cost per unit 
change in HbA1c (mmol/mol). This is based on the difference in mean total cost per 
patient between the intervention and control group (home and hospital 
management), divided by the difference in mean HbA1c. The resulting incremental 
cost-effectiveness ratio (ICER) was compared with reference to what the NHS is 
willing to pay (WTP) for an additional unit change in HbA1c; this being inferred from 
existing interventions in diabetes. 
A cost consequences analysis (CCA) was conducted, in which the costs and 
outcomes are presented in a tabular format to support decision makers and allow 
them to attach their own weighting to each result. These outcomes include measures 
of physical, psychological and social consequences based on parent answers about 
their child.  
Analytical methods 
Data collected were inputted into IBM SPSS Version 25 for analysis.[26] The data 
were assessed for accuracy and missing data. Any outliers identified were checked 
against the original CRF and then investigated through a sensitivity analysis. An 
analysis of randomness was carried out on missing data to compare against 
patients’ socio-demographic data.[27] If participants left a blank response, we 
assumed that zero items of resources were used. 
Uncertainty in the cost-effectiveness ratio was considered by use of non-parametric 
bootstrapping using Stata.[28] This involved sampling (with replacement) pairs of 
mean cost and HbA1c 10,000 times as a means of estimating the sampling 
distribution.[29] Separate regression analyses were conducted to adjust total costs (by 
arm and centre) and 24 month HbA1c (on arm, centre and baseline HbA1c). This 
produced 95% confidence intervals for each cost variable and the differences in both 
costs and effect for calculating the ICER. This was done for direct healthcare costs 
with and without patient or carer borne costs. Microsoft Excel was then used to 
bootstrap HbA1c and total direct healthcare costs at 24 months (1000 replications) 
and results are displayed on a cost-effectiveness plane. The cost-effectiveness plane 
is used to visually represent the differences in costs and health outcomes between 
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arms in two dimensions. A cost-effectiveness  acceptability curve (CEAC) was drawn 
to represent the probability of cost-effectiveness for different values of WTP.[30] This 
was repeated for the wider perspective, encompassing direct non-healthcare costs 
and indirect productivity losses. The CEAC is used to summarise the impact of 
uncertainty on the result of an economic evaluation. It represents the probability of an 
intervention being cost-effective for any given value of the cost-effectiveness 
threshold. 
A univariate sensitivity analysis was also conducted, adjusting the cost of an 
overnight stay in hospital for an alternative value, to assess the impact on the ICER. 
Reporting 
The economic analysis of DECIDE is reported in accordance with the Consolidated 
Health Economic Evaluation Reporting Standards (CHEERS).[31] 




Of the 203 children involved in the trial, one participant dropped out within the first 
few days, eight were missing a 24-month HbA1c measurement and one patient did 
not have a baseline HbA1c. Therefore, the primary analysis of the clinical data 
reported results on the remaining 193 participants. To ensure consistency and allow 
for calculation of the ICER, the same participants were included in the economic 
analysis.   
Healthcare outcomes 
The DECIDE trial found no significant difference in HbA1c at 24 months between 
home and hospital management (72.1mmol/mol and 72.6mmol/mol; p=0.863, 
respectively). This was not affected by repeated measures or sensitivity analyses. 
Baseline characteristics were explored and both groups were considered to have 
reasonable similarities.[14]  
Direct healthcare resource use and costs 
Over 24 months, home management was less costly than hospital management (-
£2,217; 95% CI -£2,825 to -£1,609; p<0.001) (Table 1). The greatest difference in 
direct NHS costs, in favour of home management, was seen during days 0-3 (-
£2,223; 95% CI -£2,373 to -£2,072; p<0.001). During this time, participants in the 
home management group had fewer contacts with consultants and junior doctors but 
more non face-to-face interactions with nurses (i.e. telephone calls and email 
correspondence) (Table 2). Overall, this led to costs during days 0-3 of £974 per 
child for home management and £720 for hospital management, in terms of contacts 
with the Diabetes Team (mean difference in cost of £254; 95% CI £147 to £361; 
p<0.001). The cost of nurse travel was also significantly higher for home 
management (mean difference £115; 95% CI £86 to £143; p<0.001). However, this 
increased expense was outweighed by the cost of the hospital stay in the first three 
days for those in the hospital group (£2,583; 95% CI £2,464 to £2,702 per child). 
This had the greatest contribution to the total direct healthcare costs. 
Non-healthcare resource use and costs 
There were no significant differences between home or hospital in either the number 
of days off school or work during the initiation period (0-3 days) (Table 2); and this 
remained similar between groups over the 24-month follow-up period. Home 
management was not found to be significantly less costly than hospital management 
for patients and their carers at 0-3 days (-£21; 95% CI -£101 to £59; p=0.607) or 24 
months (£338; 95% CI -£963 to £286; p=0.288) (Table 1).  
Healthcare and non-healthcare costs 
Overall, home management was significantly less costly than hospital management 
for the base case analysis (-£2217; 95% CI -£2,825 to -£1,609, p<0.001). The 
difference in costs to the patient and their carers between home and hospital 
management was not statistically significant. However, adopting a wider perspective 
which encompasses direct NHS costs and patient/carer borne costs, led to home 
management being significantly less costly (-£2,556; 95% CI -£3,494 to -£1,618; 
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p<0.001) (Table 3). Full costs, confidence intervals and significance levels for all 
resource use data collected are presented in Supplementary Materials Table 8-13.
Page 10 of 22 
 
Table 1 Costs relating to resource use 
 Home management (n=98), 
mean (95% CI) (£) 
Hospital management 
(n=95), mean (95% CI) (£) 
Difference between Home 




Home and Hospital 
DIRECT HEALTHCARE COSTS     
Days 0-3 Contact with diabetes team 974 (889 to 1059) 720 (658 to 782) 254 (147 to 361) <0.001 
Other Health Professionals  0 (-0. to 0) 1 (-1 to 4) -1 (-4 to 1) 0.223 
Tests and Investigations 55 (49 to 61) 62 (56 to 67) -7 (-15 to 1) 0.100 
Hospital stay 0 2583 (2464 to 2702) -2583 (-2702 to -2463) <0.001 
Nurse travel 133 (107 to 159) 18 (8 to 28) 115 (86 to 143) <0.001 
Dietician travel  3 (1 to 5) 1 (-1 to 2) 2 (0 to 5) 0.039 
Total cost days 0-3 1163 (1079 to 1248) 3386 (3261 to 3511) -2223 (-2373 to -2072) <0.001 
Follow-up 
(24months) 
Contact with the diabetes 
team 
1984 (1876 to 2092) 2017 (1915 to 2119) -33 (-182 to 116) 
0.664 
- Outpatient Visits 1400 (1344 to 1455) 1392 (1341 to 1443) 8 (-67 to 83) 0.837 
- Contact with the 
diabetes team 
(other) 
584 (502 to 667) 625 (541 to 709) -41 (-160 to 79) 
0.502 
Hospital contacts 897 (569 to 1225) 860 (553 to 1167) 37 (-413 to 487) 0.874 
Tests and Investigations  8 (5 to 11) 8 (6 to 11) -1 (-4 to 4) 0.968 
Total Insulin  457 (402 to 512) 446 (397 to 495) 11 (-63 to 85) 0.773 
Equipment 1745 (1567 to 1924) 1714 (1544 to 1883) 31 (-218 to 281) 0.803 
Other Health Professional 
Visits 
195 (149 to 241 to 08) 236 (177 to 295) -41 (-115 to 33) 
0.278 
Total follow-up cost 5287 (4864 to 5709) 5282 (4883 to 5680) 5 (-584 to 594) 0.986 
Total cost at 24months 6450 (6004 to 6897) 8668 (8255 to 9080) -2217 (-2825 to -1609) <0.001 
PATIENT/CARER COSTS     
Days 0-3 Days off school 66 (56 to 75) 57 (47 to 67) 8 (-5 to 22) 0.235 
Days off work 250 (203 to 297) 256 (201 to 310) -5 (-77 to 66) 0.886 
Travel 11 (9 to 12) 18 (15 to 21) -8 (-11 to -4) <0.001 
Out of pocket expenses 8 (7 to 10) 22 (17 to 27) -14 (-19 to -8) <0.001 
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Total cost days 0-3 331 (280 to 383) 352 (292 to 412) -21 (-101 to 59) 0.601 
Follow-up 
(24months) 
Days off school  443 (363 to 523) 454 (349 to 559) -11 (-143 to 122) 0.871 
Days off work 869 (609 to 1128) 1180 (679 to 1681) -312 (-871 to 247) 0.275 
Travel  63 (56 to 71) 61 (49 to 72) 3 (-11 to 17) 0.687 
Out of pocket expenses  44 (32 to 56) 42 (30 to 54) 2 (-15 to 20) 0.779 
Total follow-up cost 1420 (1134 to 1705) 1737 (1207 to 2267) -317 (-916 to 281) 0.297 
Total cost at 24months 1751 (1448 to 2054) 2089 (1547 to 2631) -338 (-963 to 286) 0.290 
TOTAL COST 8201 (7585 to 8817) 10757 (10050 to 11463) -2556 (-3494 to -1618) <0.001 
 
Table 2 Units of resource use 
 Home Management (n = 98) Hospital Management (n = 95) 
Median Range Median Range 
Minimum Maximum Minimum Maximum 
DIRECT HEALTHCARE RESOURCE USE       
Days 0-3 Contacts with the diabetes team       
- Consultant 1.0 0.0 9.0 2.0 0.0 5.0 
- Junior doctor 1.0 0.0 5.0 3.0 0.0 10.0 
- Nurse       
• Face to face 6.0 0.0 13.0 6.0 0.0 32.0 
• Telephone calls/emails 2.0 0.0 28.0 0.0 0.0 3.0 
- Dietitian 1.0 0.0 3.0 1.0 0.0 3.0 
Other health care professionals 0.0 0.0 1.0 0.0 0.0 2.0 
Test and investigations       
- Diagnosis related 4.0 0.0 8.0 5.0 1.0 12.0 
- Other 2.0 0.0 4.0 3.0 0.0 6.0 
Hospital stay (days) 0.0 0.0 0.0 3.0 0.0 6.0 
Travel       
- Nurse travel distance (miles) 40.0 0.0 214.0 0.0 0.0 192.0 
- Dietician travel distance (miles) 0.0 0.0 24.0 0.0 0.0 32.0 
Contacts with the diabetes team       




- Outpatient* 9.0 6.0 18.0 9.0 6.0 16.0 
- Other** 28.5            2.0 128.0 31.0 2.0 158.0 
Hospital contacts       
- A&E 0.0 0.0 8.0 0.0 0.0 6.0 
- Ward 0.0 0.0 16.0 0.0 0.0 8.0 
Tests and investigations*** 0.0 0.0 11.0 0.0 0.0 8.0 
Insulin 18889.5 2138.0 64354.0 19669.0 2351.5 48858.0 
Other health professionals       
- GP 2.0 0.0 14.0 2.0 0.0 19.0 
- Nurse 1.0 0.0 8.0 0.0 0.0 31.0 
- Other 0.0 0.0 11.0 0.0 0.0 22.0 
PATIENT/CARER RESOURCE USE       
Days 0-3 Days off school 2.0 0.0 5.0 2.0 0.0 5.0 
Days off work 2.0 0.0 9.0 2.0 0.0 14.0 
Travel (hours) 2.0 0.0 7.0 3.0 0.0 16.0 
Out of pocket expenses (£) 11 0 38 16 0 87 
Follow-up 
(24months) 
Days off school  11.0 0.0 64.0 11.0 0.0 129.0 
Days off work 3.3 0.0 70.0 4.0 0.0 164.0 
Travel (hours) 10.0 0.0 96.0 9.0 0.0 92.0 




Days off school 13.0 0.0 66.0 13.5 0.0 132.0 
Days off work 5.0 0.0 78.0 6.5 0.0 167.5 
Travel (hours) 12.0 3.0 99.0 13.0 0.0 94.0 
Out of pocket expenses (£) 43 0 546 48 0 555 
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Cost effectiveness 
Home management dominated hospital management. In the base case analysis, the ICER 
was £7,434 saved per additional mmol/mol reduction of HbA1c (Table 3). Based on the 
bootstrapped analysis for consideration of the joint uncertainly in costs and effects, the cost-
effectiveness plane shows that home management has the potential to be cost saving for the 
NHS without changing clinical effectiveness (Figure 1a). The cost-effectiveness acceptability 
curve (CEAC) is somewhat counterintuitive for cost-saving interventions, in that the 
probability of home management being cost-effective reduces to 50% when the willingness 
to pay increases to £7,770 per unit reduction of HbA1c (mmol/mol) (Figure 1b).  
An alternative unit cost for an overnight paediatric stay in hospital was explored through a 
univariate sensitivity analysis. This figure was based on a previous study,[32]  inflated to the 
current year, to give a value of £692. This had no significant impact on the ICER (£5,451 
saving per additional unit reduction in HbA1c (mmol/mol)) and the difference in direct 
healthcare costs between home and hospital at 24 months remained statistically significant 
(Table 3 and Supplementary Materials Figure 2).  
Adopting a broader cost perspective by incorporating both direct healthcare and non-
healthcare costs, the ICER increased to £8,585 saving per additional mmol/mol reduction of 
HbA1c (Table 3). This does not have a significant effect on the distribution on the cost-
effectiveness plane or on the probability of home management being cost-effective 
(Supplementary Materials Figure 1). Home management remained the dominant strategy. 
Cost Consequences Analysis 
A table presenting costs alongside psychological, physical and social consequences 
reported in the main trial is displayed in Supplementary Materials Table 14. Outcomes are 
taken from the child questionnaires.  
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to -1581.477, <0.001 












to -1575.701, <0.001 










to -1002.370, <0.001 







50.3 48.4 47.6 
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Discussion  
This economic evaluation was designed to assess whether delivering management 
at home for children with T1D who are clinically well at diagnosis would represent a 
cost-effective strategy for the NHS. The results indicate that the difference between 
home and hospital management in terms of direct NHS costs over 24 months, of 
£2,182 per patient, favours home management. Uncertainty analysis indicated that 
the probability of home management being cost saving was 1.0. The greatest driver 
of differences in healthcare costs was the cost of hospitalisation during the initiation 
period. The ICER for the base-case analysis indicated that home management was 
dominant, with £7,434 saved per additional unit reduction in mmol/mol of HbA1c. 
Sensitivity analysis indicated that the cost-effectiveness was stable to the choice of 
which costs were included. However, there is considerable uncertainty around the 
difference in effect (HbA1c), reflected in the probability of the cost-effectiveness on 
the CEAC being ~0.5 even at high thresholds of willingness to pay.  
Strengths and weaknesses 
The major strength of this evaluation is that it is based on an RCT, which reduces 
the risk for potential bias and uses patient-level data. The analysis was conducted in 
line with the main trial to ensure consistency and methods followed the NICE 
reference case.  
A limitation of this study is that QALYs were not used as the measure of health 
outcome. The main trial did not collect data on health-utility in order to estimate 
QALYs due to the lack of a validated paediatric utility measure at the time of study 
commencement, especially in younger children.[33] Therefore, we are unable to 
determine whether the ICER would be acceptable, given the NICE threshold of 
£20,000-30,000 per QALY. However, HbA1c is known to be a useful surrogate 
outcome measure in assessing the effectiveness of interventions for T1D as it is 
positively associated with an increased risk of long-term complications.[34,35] The 
ADaPT study of a diabetes-specific psychological intervention administered by 
diabetes nurses is an example of a trial which reports costs alongside HbA1c 
improvement, in addition to QALYs. The authors state that basing cost-effectiveness 
on HbA1c outcomes rather than QALYs can lead to higher probabilities of cost-
effectiveness and this is an important point to be aware of when interpreting our 
results.[36] However, their ICER of £457 per 1mmol/mol decrease in HbA1c is based 
on spending more for decreases in HbA1c, not saving costs as in our ICER, and 
therefore is not comparable for interpreting WTP. 
This leads to a second limitation in that we chose not to perform long-term 
extrapolation to assess the cost-effectiveness over a patient’s lifetime. Life-time 
extrapolation relies on economic models which use QALYs as the measure of effect. 
However, despite many models existing for use in T1D, a lack of validation in the 
paediatric setting undermines their application in the context of the DECIDE trial.[37] 
Moreover, as there was no statistically significant difference in clinical effectiveness, 
this would also require assumptions on long-term benefits which could introduce 
bias.  
The accuracy of the final unit costings may have been impacted by varying 
interpretation of case report forms and ability to recall, as parents were asked to 
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recall answers by nurses who then completed the forms. However, questions about 
resource use were limited to a 3-month recall period, which is the general recall 
period for trial-based economic evaluations.[38] Completion rates of forms were also 
high, with a small proportion of missing data. In addition, there are a number of 
methodological challenges in assigning costs to days of missed schooling, with no 
clear consensus on the most appropriate approach.[39] We costed the time taken off 
school based on calculating an average cost spent per pupil per day, based on the 
Annual Report on Education Spending in England.[24] This may underestimate the 
economic consequences of forgone leisure time and educational achievement. 
A final limitation is that there have been changes in practice and consequently 
resource use and costs since the trial commenced. For example, test and 
investigation use was costed from one site only and this figure is likely to differ 
across centres. However, all costs were updated to, or based on, most recent figures 
to ensure relevance to the current NHS costs and any differences between sites to 
the overall outcomes was considered likely to be small and therefore unlikely to 
effect the overall findings. It should also be noted that at the time this study was 
conducted, few patients were using continuous glucose monitoring to allow us to 
collect data on ‘time in range’. 
Context in the current literature 
This is the first cost-effectiveness evaluation to compare home versus hospital 
management of T1D at diagnosis in children and young people in a UK setting. 
Costs were based on the UK healthcare system (NHS) and taken from national UK 
databases. The trial was conducted over eight different centres throughout the UK 
and hospital management was pragmatic, following local standard practice, which 
increases our confidence in the generalisability of the results to other areas of the 
UK.  
The findings of this evaluation are comparable to other studies.[5,13] However, 
interpretation of previous studies is limited by the use of small sample sizes, non-UK 
settings and all of them involved ‘hybrid’ models of care; meaning ‘home 
management’ involved care within the hospital and home/outpatient setting. 
Therefore, previous studies have not evaluated home care exclusively from the day 
of diagnosis and their reproducibility within the UK healthcare setting may be limited.  
Implications for practice and research 
Home management led to significant cost reductions for the NHS at both three days 
and 24 months. This economic evaluation, alongside the main trial provides 
evidence for home care being the first line approach for management of T1D at 
diagnosis in children who are clinically well. However, since the start of this trial, 
education has become more intensive and insulin delivery and blood glucose 
monitoring more complex. As a result, many centres choose to admit all patients by 
default, despite NICE guidance supporting home management.[10] The identified 
cost-saving of around £2,000 per patient (over 2 years) could be invested in 
community services to manage this increased demand on healthcare professionals, 
increasing the feasibility of delivering a package of care which would normally be 
delivered in hospital.  
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It is envisaged that the results of this analysis will contribute to the evidence 
supporting future updates of NICE Guidelines on management of T1D in children 
and adolescents at diagnosis. Further research could involve testing a hybrid model 
of care within the UK-setting, incorporating updates in the management approach, 
and measuring costs and utility.   
Conclusion 
Home management from diagnosis of T1D for children who are medically stable 
represents a saving of £2,182 per patient with no significant impact on clinical 
effectiveness. These findings add to the main DECIDE trial which demonstrated that 
home management at the onset of T1D did not lead to any significant differences in 
glycaemic control. With incidence of T1D increasing and the demand for hospital 
beds rising, implementation of this approach as standard practice could prove to be 
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Figure 1 













Figure 1  
 (a) Reduction in HbA1c represents improvement.  
    =  point estimate ICER £7,434 per mmol/mol reduction of HbA1c (-0.294, -£2,182) 
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